Neuberger Berman High Yield Strategies Fund EBIT

The latest EBIT for NHS is $42M as of April 2026. That compares with $46M in the prior-year period — down 8.4% year over year. That is above the sector sector average of $-9.6M. Investors often review this figure alongside Neuberger Berman High Yield Strategies Fund's historical trend and sector peers before judging valuation or financial health.

Over the past year, NHS's EBIT moved from $46M to $42M — a 8.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Neuberger Berman High Yield Strategies Fund's operating scale or balance-sheet position.

Against its sector companies, NHS currently prints $42M for EBIT, while the sector average sits near $-9.6M. That is roughly 534.4% above the sector mean. Large gaps often invite a closer look at Neuberger Berman High Yield Strategies Fund's growth, margins, and balance sheet.

A EBIT figure of $42M for NHS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-9.6M. Explore the charts below for those layers of context.

After noting NHS's EBIT ($42M), review year-over-year change from $46M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.